Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

Gozetotide binds to the cancer cells with prostate-specific membrane antigen (PSMA) on their surface, making them visible ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

A common imaging workup may include a bone scan and a CT scan of the abdomen and pelvis. An MRI might be done as well. Some research centers are also using magnetic MRIs or PET scans to further refine ...

PYLARIFY has made a profound impact on the lives of patients battling prostate cancer. It is the number one ordered PSMA PET imaging agent in the U.S., and is a proven diagnostic backed by real-world ...

WVU Medicine St. Joseph’s Hospital is proud to announce the addition of two cutting-edge imaging services: PET/CT and Prostate MRI. These advanced technologies provide enhanced diagnostic capabilities ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

Scans found primary cancer in his prostate, which has metastasised to his bones. Laura Kerby, chief executive at Prostate Cancer UK, points out that Hoy only found out he had prostate cancer ...

These findings highlight the receptor’s potential as a therapeutic target for preventing epilepsy. The study also introduces a promising diagnostic approach using PET scans to measure P2X7 receptor ...